Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.

Cryotherapy Effect

An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.

Cooral™

Oral cooling by ice chips or crushed ice or ice pop

cryotherapy

Linköping University Hospital

Karolinska University Hospital

Uppsala University Hospital

Örebro University Hospital

Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study

Assesment with OMAS is done by a dentist blinded to treatment group, three times a week during 28 days or until discharge. Assessment with the not blinded to the treatment group, three times a week during 28 days or until discharge.

Uppsala University

Cryotherapy during conditioning treatment with chemotherapy prior to HSCT

Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT

Oral Mucositis

Pain

Infection

Nutrition Aspect of Cancer

Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.

Cryotherapy

Pediatric Oncology Department, Queen Silvia Childrens´ Hospital

Departent of Pediatric Oncology, Lund University Hospital

Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Hudding

Department of pediatrics B78, Karolinska University Hospital

Department of Hematology, Uppsala University Hospital

Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation

A Randomized Controlled Trial of Cryotherapy for Prevention and Reduction of Severity of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.

WHO-Oral toxicity scale Grade 0 - No mucositis Grade 1 - Erythema and/or soreness Grade 2 - Erythema and/or ulcers. Can eat solid food. Grade 3 - Erythema and/or Ulcers. No solid food but can ingest liquids. Grade 4 - Oral alimentation not possible.

Mouth Pain measured with Numerical Rating scale(NRS)for children >7 years and parents and Facial Pain Scale(FPS) for children < 7 years

Beck youth inventories for depression and anxiety

Days with, and dose of morphine-equivalent opioids

Weight Loss in kilograms from admission to date of engraftment

Counted from day 0 until discharge either home or to region hospital.

Level of p-CRP in comparison to grade of mucositis

In correlation to grade of Oral Mucositis

The Swedish Childhood Cancer Foundation

Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle

Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
Abraxane: Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
Carboplatin: area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days

Abraxane, Carboplatin

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

The primary objective of the trial is to statistically test whether Abraxane® and carboplatin can improve progression-free survival (PFS) as compared to historical controls.

The proportion of patients experiencing any neurotoxicity will be tabulated by grade. The proportion of patients experiencing ≥ grade 3 non-hematologic toxicities (excluding neurotoxicity) and the proportion of patients experiencing ≥ grade 3 hematologic toxicities will be calculated with their exact 80% confidence intervals.

To Assess the Safety and Tolerability of a Combination Regimen of Weekly Abraxane® and Carboplatin to Treat Women With "Triple Negative" Stage IV Metastatic Breast Cancer

Overall Study

Dr Kimberly Blackwell

Metastatic Breast Cancer

Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days

Abraxane

area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days

Carboplatin

Duke University Medical Center

Peking University School of Oncology/Beijing Cancer Hospital

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for "Triple Negative" (Demonstrating no Expression for Estrogen, Progesterone, or Human Epidermal Growth Factor Receptor 2 (HER2)Receptors) Metastatic Breast Cancer

stomatitis/albuminas

Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study

Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu